Published by Josh White on 24th November 2025
(Sharecast News) - Novo Nordisk's attempt to repurpose its blockbuster diabetes and weight-loss drug semaglutide for Alzheimer's disease suffered a decisive setback on Monday, after two major phase three trials failed to show that the medicine could slow cognitive decline in early-stage patients.